Evidence map›Paper›PMID 42581242›Full record

ArticleLeukemia2026

USP8 controls proteostasis pathways in B cells and multiple myeloma.

Almut Dufner, Fabien Thery, Gianni Monaco, Jelena Lazarevic, Oliver Gorka, Nina Chevalier, Marta Campos Alonso, Maximilian Frosch, Gerbrand J van der Heden van Noort, Kira Allmeroth and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Almut DufnerInstitute of Neuropathology, Medical Center-University of Freiburg/Medical Faculty - University of Freiburg, Freiburg, Germany. almut.dufner@uniklinik-freiburg.de.ORCID http://orcid.org/0000-0002-9950-0691
Fabien TheryVIB-UGent Center for Medical Biotechnology, Gent, Belgium.
Gianni MonacoInstitute of Neuropathology, Medical Center-University of Freiburg/Medical Faculty - University of Freiburg, Freiburg, Germany.
Jelena LazarevicDepartment of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation University Hospital RWTH Aachen, Aachen, Germany.
Oliver GorkaInstitute of Neuropathology, Medical Center-University of Freiburg/Medical Faculty - University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-8245-3008
Nina ChevalierDepartment of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg/Medical Faculty - University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-1924-9530
Marta Campos AlonsoInstitute of Neuropathology, Medical Center-University of Freiburg/Medical Faculty - University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0009-0008-7356-6095
Maximilian FroschInstitute of Neuropathology, Medical Center-University of Freiburg/Medical Faculty - University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-5418-0962
Gerbrand J van der Heden van NoortDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.
Kira AllmerothMax Planck Institute for Biology of Ageing, Cologne, Germany.
Marco PrinzInstitute of Neuropathology, Medical Center-University of Freiburg/Medical Faculty - University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-0349-1955
Olaf GroßInstitute of Neuropathology, Medical Center-University of Freiburg/Medical Faculty - University of Freiburg, Freiburg, Germany.
Huib OvaaDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.
Paul P GeurinkDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.
Wolfgang W SchamelSignalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.
Martin S DenzelMax Planck Institute for Biology of Ageing, Cologne, Germany.
Vigo HeissmeyerInstitute for Immunology, Biomedical Center, Ludwig-Maximilians-Universität München, Planegg-Martinsried, Germany.
Benedikt JacobsDepartment of Internal Medicine 5, Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Mirle SchemionekDepartment of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation University Hospital RWTH Aachen, Aachen, Germany.ORCID http://orcid.org/0000-0002-5947-3529
Francis ImpensVIB-UGent Center for Medical Biotechnology, Gent, Belgium.
Heiko BrunsDepartment of Internal Medicine 5, Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Klaus-Peter KnobelochInstitute of Neuropathology, Medical Center-University of Freiburg/Medical Faculty - University of Freiburg, Freiburg, Germany. klaus-peter.knobeloch@uniklinik-freiburg.de.ORCID http://orcid.org/0000-0003-1587-1944

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 331065168Deutsche Forschungsgemeinschaft (German Research Foundation) 423813989/GRK2606Deutsche Forschungsgemeinschaft (German Research Foundation) CIBSS-EXC-2189-Project ID 390939984Deutsche Forschungsgemeinschaft (German Research Foundation) CIBSS - EXC-2189 (Project ID 390939984)Deutsche Forschungsgemeinschaft (German Research Foundation) EXC-2189 - Project ID: 390939984Deutsche Forschungsgemeinschaft (German Research Foundation) EXC-294Deutsche Forschungsgemeinschaft (German Research Foundation) GRK 2606 (Project ID 423813989)Deutsche Forschungsgemeinschaft (German Research Foundation) KN590/4-2Deutsche Forschungsgemeinschaft (German Research Foundation) Project-ID 403222702 - SFB 1381Deutsche Krebshilfe (German Cancer Aid) 70114489Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 12AN524NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) G0F8616N
6 · The paper itself

Abstract

Ubiquitin-specific protease 8 (USP8) plays a pivotal role in the regulation of endosomal and lysosomal trafficking and is critically involved in the pathogenesis of various tumor entities. USP8 represents a vulnerability gene in multiple myeloma (MM), suggesting a functional role in the B- and plasma cell compartment. Here we analyzed mice with stage-specific Usp8 deletion during B-cell development and investigated its role in patient-derived MM cells that are sensitive or resistant to the proteasome inhibitor Bortezomib (BTZ) using USP8 depletion and treatment with DUB-IN-2, a reported USP8 inhibitor. Usp8 depletion in Usp8

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.